ALK+ ALCL

Pediatric Oncology The Use of Crizotinib Neutralizes Differences in Event-Free Survival in Paediatric Patients with Different Morphologic Subtypes of ALK-positive Anaplastic Large Cell Lymphoma
Dmitry Abramov • Anna Fedorova • Kirill Voronin • Pavel Levin • Veronika Fominykh • Egor Volchkov • Natalia Myakova • Dmitry Konovalov
doi.org/10.69690/ODMJ-018-0425-1973